MOLECULAR AND IMMUNE INTERDICTION OF AIDS

到目前为止，治疗性干预未能预防或控制 感染人类免疫缺陷病毒(HIV)。发展 新的战略需要多学科的努力，包括 精通广泛的医学科学的个人。这个 AECOM艾滋病研究中心的主要优势在于 关于它的高度互动研究的历史，一般和 尤其是艾滋病。AECOM的专家研究人员一直专注于 HIV感染及其对胎儿影响的研究进展 婴儿和孕妇我们的调查导致了 异常良性疾病病程和病程患者的识别 免疫监视干扰的可能机制 艾滋病毒经胎盘传播。这些发现是 建议对艾滋病的分子和免疫阻断研究。 在临床研究和基础研究的共同努力下 科学，我们将集中在几个领域：(1)识别和 优化的人和小鼠中和抗体的开发； (2)艾滋病疫苗的抗独特型和分枝杆菌载体； 通过细胞对HIV复制周期的干扰 HIV表达的调控机制；(4)细胞和分子 利用细胞分析HIV在神经系统中的复制 品系、器官类型培养和胎儿脑组织。 儿童和成人；(5)分子表征 艾滋病中的弓形虫病。跨学科协作将 通过几个共享设施进行培育：(1)翻新 为集中管理和协调提供充足的空间 临床和基础研究核心(Mazer)。该设施还将 召开集中数据管理和艾滋病指定会议 机房；(2)开发共享的研究核心设施 包括：流式细胞术；杂交瘤设备；寡核苷酸和 多肽合成设施；(3)分配资金用于两个新的 调查人员、新举措和危机支持以加强 新颖的想法和确保研究工作的连续性。CFAR 参与的AECOM调查人员通过以下方式高度互动 部门关系，艾滋病研究计划的成员 在癌症中心。其中包括国家认可的 临床研究人员和科学家，其中三人是 美国国家科学院。

Therapeutic interventions have so far failed to prevent or control infection with the human immunodeficiency virus (HIV). Development of novel strategies requires a multidisiplinary effort including individuals skilled in a broad range of the medical sciences. The major strength of the AECOM Center for AIDS Research (CFAR) rests up on its history of highly interactive research in general and in AIDS in particular. Expert researchers ar AECoM have focused for years on the study of HIv infection in and its effect on fetuses infants and pregnant women our investigations have lead to the identification of patients with unusually benign disease course and of the possible mechanisms of immune surveillance interfering with transplacental transmission of HIV. These findings are the key for the proposed research on molecular and immune interdiction of AIDS. In a concerted effort of clinical investigations and basic sciences, we will focus on several areas: (1) Identification and development of optimized human and murine neutralizing antibodies; (2) Antiidiotypes and mycobacterial vectors for AIDS vaccines; (3) Interference with the HIv replication cycle through cellular regulatory mechanisms of HIv expression; (4) Cellular and molecular analysis of HIv replication in the nervous system utilizing cell lines, organotypic cultures and brain tissues from fetuses. children and adults; (5) Molecular characterization of Toxoplasmosis in AIDs. The interdisciplinary collaboration will be fostered through several shared facilities: (1) The renovation of ample space for a centralized administrative and coordinative clinical and basic research core (Mazer). This facility will also house a centralized data management and AIDS-designated conference rooms; (2) Development of shared research core facilities including: Flow cytometry; Hybridoma facility; oligonucleotide and peptide synthesizing facility; (3) Funds are allocated for two new investigators, new initiatives and for crisis support to enhance novel ideas and ensure continuity of research efforts. The CFAR participating AECOM investigators are highly interactive through departmental affiliations, membership in the AIDS Research program and in the Cancer Center. They include nationally recognized clinical researchers and scientists, three of whom are members of the National Academy of Science.